Companies / Amylyx Pharmaceuticals, Inc. / Activity

Activity — Amylyx Pharmaceuticals, Inc.

37 moves.

Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
InsidersInstitutions
DateActorActionSecurityValueShares ΔPosition afterImpact
Mar 5, 2026Cohen Joshua B
CEO
GrantCommon Stock$0+249K
+7.46%
3,583,548
3.22% of shares
low
Mar 5, 2026Mazzariello Gina
Executive
GrantCommon Stock$0+75K
+55.54%
209,090
0.19% of shares
low
Mar 5, 2026Frates James M
Executive
GrantCommon Stock$0+96K
+57.95%
261,628
0.23% of shares
low
Mar 5, 2026Klee Justin B.
CEO
GrantCommon Stock$0+249K
+7.46%
3,583,481
3.22% of shares
low
Mar 5, 2026Bedrosian Camille L
Executive
GrantCommon Stock$0+96K
+56.70%
265,285
0.24% of shares
low
Jan 12, 2026Milne George M Jr
Director
GiftCommon Stock$0-18K
-2.14%
812,881
0.73% of shares
low
Jan 16, 2026Cohen Joshua B
CEO
ExerciseCommon Stock$21.3K+3K
+0.08%
3,381,439
3.03% of shares
low
Jan 16, 2026Klee Justin B.
CEO
ExerciseCommon Stock$21.6K+3K
+0.08%
3,381,393
3.03% of shares
low
Jan 16, 2026Cohen Joshua B
CEO
SellCommon Stock$27.3K-2K
-0.06%
3,379,465
3.03% of shares
low
Jan 16, 2026Klee Justin B.
CEO
SellCommon Stock$27.7K-2K
-0.06%
3,379,398
3.03% of shares
low
Jan 6, 2026Frates James M
Executive
SellCommon Stock$37.0K-3K
-1.84%
177,104
0.16% of shares
low
Feb 23, 2026Mazzariello Gina
Executive
SellCommon Stock$48.4K-3K
-2.36%
141,274
0.13% of shares
low
Feb 2, 2026Mazzariello Gina
Executive
SellCommon Stock$50.5K-3K
-2.33%
144,693
0.13% of shares
low
Feb 2, 2026Frates James M
Executive
SellCommon Stock$52.1K-4K
-2.01%
173,547
0.16% of shares
low
Jan 6, 2026Klee Justin B.
CEO
SellCommon Stock$85.6K-8K
-0.23%
3,317,586
2.98% of shares
low
Jan 6, 2026Cohen Joshua B
CEO
SellCommon Stock$85.6K-8K
-0.23%
3,317,632
2.98% of shares
low
Mar 2, 2026Bedrosian Camille L
Executive
SellCommon Stock$94.2K-6K
-3.68%
169,295
0.15% of shares
low
Mar 2, 2026Mazzariello Gina
Executive
SellCommon Stock$99.4K-7K
-4.84%
134,430
0.12% of shares
low
Mar 2, 2026Frates James M
Executive
SellCommon Stock$114.9K-8K
-4.56%
165,638
0.15% of shares
medium
Feb 2, 2026Cohen Joshua B
CEO
SellCommon Stock$227.6K-16K
-0.46%
3,363,965
3.02% of shares
medium
Feb 2, 2026Klee Justin B.
CEO
SellCommon Stock$227.6K-16K
-0.46%
3,363,898
3.02% of shares
medium
Mar 2, 2026Klee Justin B.
CEO
SellCommon Stock$423.8K-29K
-0.87%
3,334,616
2.99% of shares
medium
Mar 2, 2026Cohen Joshua B
CEO
SellCommon Stock$424.1K-29K
-0.87%
3,334,683
2.99% of shares
medium
Jan 15, 2026Klee Justin B.
CEO
ExerciseCommon Stock$1.49M+197K
+5.94%
3,514,739
3.15% of shares
low
Jan 15, 2026Cohen Joshua B
CEO
ExerciseCommon Stock$1.49M+197K
+5.94%
3,514,814
3.15% of shares
low
Jan 15, 2026Klee Justin B.
CEO
SellCommon Stock$1.85M-136K
-3.87%
3,378,546
3.03% of shares
medium
Jan 15, 2026Cohen Joshua B
CEO
SellCommon Stock$1.85M-136K
-3.87%
3,378,621
3.03% of shares
medium
Jun 4, 2026Milne George M Jr
Director
GrantStock Option (right to buy)—+24K
24,372
0.02% of shares
low
Mar 5, 2026Cohen Joshua B
CEO
GrantStock Option (Right to Buy)—+373K
373,295
0.34% of shares
low
Mar 5, 2026Mazzariello Gina
Executive
GrantStock Option (Right to Buy)—+112K
111,990
0.10% of shares
low
Mar 5, 2026Frates James M
Executive
GrantStock Option (right to buy)—+144K
143,985
0.13% of shares
low
Mar 5, 2026Klee Justin B.
CEO
GrantStock Option (Right to Buy)—+373K
373,295
0.34% of shares
low
Mar 5, 2026Bedrosian Camille L
Executive
GrantStock Option (Right to Buy)—+144K
143,985
0.13% of shares
low
Jan 16, 2026Cohen Joshua B
CEO
ExerciseStock Option (Right to Buy)—-3K
-100.00%
0
0.00% of shares
low
Jan 15, 2026Cohen Joshua B
CEO
ExerciseStock Option (Right to Buy)—-197K
-98.59%
2,818
<0.01% of shares
low
Jan 16, 2026Klee Justin B.
CEO
ExerciseStock Option (Right to Buy)—-3K
-100.00%
0
0.00% of shares
low
Jan 15, 2026Klee Justin B.
CEO
ExerciseStock Option (Right to Buy)—-197K
-98.58%
2,847
<0.01% of shares
low
← PrevPage 1 of 1Next →